Recent Advances in the Development of Dopamine D3Receptor Antagonists: a Medicinal Chemistry Perspective
- 18 March 2011
- journal article
- review article
- Published by Wiley in ChemMedChem
- Vol. 6 (7), 1152-1162
- https://doi.org/10.1002/cmdc.201000538
Abstract
Dopamine (DA) D3 receptor antagonism might play a significant role in different therapeutic areas. A high number of preclinical studies on DA D3 receptor antagonists have shown efficacy in animal models of Parkinson’s disease, schizophrenia and drug dependence. This Review covers the activities of medicinal chemists in this field over the last ten years towards the identification of truly selective compounds. Both primary and patent literature is reviewed here. Since the original discoveries, a clear trend towards the optimization of the developability properties of the new scaffold has clearly emerged with time, from both academic and industrial researchers. Examples of advanced leads from academia and industry are described. The latest potential therapeutic applications are reported too.Keywords
This publication has 67 references indexed in Scilit:
- Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective AntagonistScience, 2010
- A Series of 18F-Labelled Pyridinylphenyl Amides as Subtype-Selective Radioligands for the Dopamine D3 ReceptorChemMedChem, 2010
- Characterization of the Transport, Metabolism, and Pharmacokinetics of the Dopamine D3 Receptor-Selective Fluorenyl- and 2-Pyridylphenyl Amides Developed for Treatment of Psychostimulant AbuseThe Journal of pharmacology and experimental therapeutics, 2010
- Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disordersAnnals of the New York Academy of Sciences, 2010
- N-(4-(4-(2,3-Dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with Functionalized Linking Chains as High Affinity and Enantioselective D3 Receptor AntagonistsJournal of Medicinal Chemistry, 2009
- New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systemsBioorganic & Medicinal Chemistry Letters, 2008
- 1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A Series of Potent and Selective Dopamine D3 Receptor AntagonistsJournal of Medicinal Chemistry, 2007
- Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivativesBioorganic & Medicinal Chemistry Letters, 2006
- Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists: 1H-Pyrimidin-2-one derivativesBioorganic & Medicinal Chemistry Letters, 2006
- Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neurolepticsNature, 1990